Uncategorized

Cambridge Polymer Group receives a U.S. patent allowance for injectable hydrogel

Cambridge Polymer Group received a U.S. patent allowance for its injectable hydrogel formulations for biomedical applications. The patent addresses methods for preparing a biocompatible liquid that gels in vivo without chemical reaction. CPG is developing this technology for nucleus pulposus augmentation, orthopedic applications, synthetic tissue models, and tissue bulking.

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button